2013
HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes
Lipska KJ, Warton EM, Huang ES, Moffet HH, Inzucchi SE, Krumholz HM, Karter AJ. HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes. Diabetes Care 2013, 36: 3535-3542. PMID: 23900589, PMCID: PMC3816866, DOI: 10.2337/dc13-0610.Peer-Reviewed Original ResearchConceptsSevere hypoglycemiaType 2 diabetesRelative riskGlycemic controlSelf-reported severe hypoglycemiaType 2 diabetic patientsGlucose-lowering therapyPoor glycemic controlRate of hypoglycemiaPotential effect modifiersIntegrated healthcare systemYears of ageEligible survey respondentsPoisson regression modelsDiabetes durationDiabetes medicationsDiabetic patientsClinical variablesDiabetes StudyNormal glycemiaMain exposureEffect modifiersHypoglycemiaType 2Patients
2012
State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning
Ross JS, Jackevicius C, Krumholz HM, Ridgeway J, Montori VM, Alexander GC, Zerzan J, Fan J, Shah ND. State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning. Health Affairs 2012, 31: 188-198. PMID: 22232110, PMCID: PMC3319744, DOI: 10.1377/hlthaff.2011.1068.Peer-Reviewed Original ResearchConceptsState Medicaid programsPreferred drugDrug listPrior authorizationMedicaid programSafety warningsPrior authorization programHigh-cost drugsDiabetes medicationsPrescribing ratesEffective prescribingSafe prescribingMedicaid beneficiariesDiabetes drugsPrescribingState MedicaidHeart attackRosiglitazoneDrug availabilityDrugsAuthorization programPrescriptionMinimal changesMedicationsProviders